%0 Generic
%A L., Zuo
%A M., Wang
%A F., Hou
%A Y., Yan
%A N., Chen
%A J., Qian
%A B., Bieber
%A R.L., Pisoni
%A B.M., Robinson
%D 2016
%T Supplementary Material for: Anemia Management in the China Dialysis Outcomes and Practice Patterns Study
%U https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Anemia_Management_in_the_China_Dialysis_Outcomes_and_Practice_Patterns_Study/5129164
%R 10.6084/m9.figshare.5129164.v1
%2 https://karger.figshare.com/ndownloader/files/8717653
%K China
%K Domestic erythropoietin stimulating agents
%K End-stage renal disease-related anemia
%K Intravenous iron
%X Background: As the utilization of hemodialysis increases in China, it is critical to examine anemia management. Methods: Using data from the China Dialysis Outcomes and Practice Patterns Study (DOPPS), we describe hemoglobin (Hgb) distribution and anemia-related therapies. Results: Twenty one percent of China's DOPPS patients had Hgb <9 g/dl, compared with ≤10% in Japan and North America. A majority of medical directors targeted Hgb ≥11. Patients who were female, younger, or recently hospitalized had higher odds of Hgb <9; those with insurance coverage or on twice weekly dialysis had lower odds of Hgb <9. Iron use and erythropoietin-stimulating agents (ESAs) dose were modestly higher for patients with Hgb <9 compared with Hgb in the range 10-12. Conclusion: A large proportion of hemodialysis patients in China's DOPPS do not meet the expressed Hgb targets. Less frequent hemodialysis, patient financial contribution, and lack of a substantial increase in ESA dose at lower Hgb concentrations may partially explain this gap. Video Journal Club ‘Cappuccino with Claudio Ronco' at http://www.karger.com/?doi=442741.
%I Karger Publishers